Intrapleural fibrinolytic therapy for pleural infection: a multicentre real-world comparison of dosing regimens Authors: Glenn Khai Wern Yong, Jonathan Jia Jun Wong, Xiaoe Zhang, Si Ling Young, Brian Lee Wei Chua, Qiao Li Tan, Imran Bin Mohamed Noor, Charlene Jin Yee Liew, Mindy Chu Ming Choong, Wui Mei Chew, Ken Junyang Goh Published: 2026 ABSTRACT AbstractBackgroundAdvances in the non-surgical management of pleural infection using intrapleural alteplase and DNase have reshaped treatment strategies. While twice-daily intrapleural fibrinolytic therapy (IPFT) is commonly used, evidence supporting once-daily regimens remains limited. We aimed to describe real-world outcomes associated with once- and twice-daily IPFT regimens and to compare their efficacy and safety, including outcomes among patients receiving modified alteplase doses.MethodsWe conducted a retrospective study of patients diagnosed with pleural infection across three tertiary referral hospitals in Singapore. Clinical, radiological, and biochemical data were analysed. Logistic regression models were used to evaluate the association between dosing frequency, dose modification, and treatment outcomes.ResultsA total of 266 patients were included. The mean age was 64 years, with a median Charlson Comorbidity Index of 3 and median RAPID (renal, age, purulence, infection source, dietary factors) score of 3. Twice-daily dosing was used in 238 patients (89.5%), while 28 patients (10.5%) received once-daily dosing. Alteplase dosing was 10 mg in 132 patients and modified (<10 mg) in 131 patients. Overall treatment success was 83.1%, with no significant difference between twice-daily and once-daily regimens (81.9% vs. 92.9%, P=0.19). On logistic regression analysis, dosing frequency was not significantly associated with treatment success or 30-day mortality. There were also no significant differences in treatment success or bleeding complications between modified and standard-dose alteplase regimens.ConclusionsIn this multicentre retrospective cohort, once-daily IPFT achieved clinical outcomes comparable to twice-daily regimens. Modified alteplase dosing (<10 mg) was similarly effective, and earlier initiation of therapy appeared to be associated with improved treatment success. Prospective studies are needed to define optimal dosing strategies, particularly in Asian populations where data remain limited.Keywords: Empyema, pleural infection, alteplase, complicated parapneumonic effusion, intrapleural fibrinolytic therapy Highlight box • Overall treatment success of intrapleural fibrinolytic therapy (IPFT) was 83.1%. • IPFT dosing frequency was not associated with treatment success, 30-day surgical intervention, readmission, 30-day mortality, or hospital length of stay. • Earlier initiation of IPFT was associated with improved treatment success. • Treatment success and bleeding rates were similar between modified (<10 mg) and standard (10 mg) alteplase dosing regimens. What is known and what is new? • Previous studies of once-daily IPFT have reported high treatment success (92.7–92.9%), although concerns have been raised regarding increased pleural bleeding. • In this multicentre retrospective cohort, once-daily IPFT achieved clinical outcomes comparable to twice-daily regimens, with no pleural bleeding events observed. What is the implication, and what should change now? • These findings provide real-world data to inform optimal IPFT dosing strategies in pleural infection. • Prospective studies and well-designed clinical trials are needed to more definitively compare dosing strategies, particularly in Asian populations where data remain limited. Introduction Pleural infections are common worldwide, with a rising incidence reported over the last two decades and are associated with considerable morbidity and mortality. Over the last decade, advances in non-surgical management have reshaped treatment approaches. The landmark MIST2 trial established that intrapleural combination therapy with tissue plasminogen activator (tPA) and DNase significantly improved drainage of infected effusions and reduced the need for surgery (1). Subsequent open-label studies have reported comparable efficacy with lower-dose alteplase regimens (2-4), contributing to heterogeneity in practice globally. Ongoing efforts to optimize the intrapleural fibrinolytic therapy (IPFT) regimen to improve administration safety and streamline services have resulted in various modifications to the original protocol, including dose attenuation of alteplase and reduction in the total number of doses (5-9). Despite these advances, data on the pharmacokinetics of intrapleural drug delivery remain scarce, and the optimal dosing strategy is uncertain. Current British Thoracic Society (BTS) guidelines recommend a twice-daily IPFT regimen (5). While a few studies have explored once-daily regimens and reported high treatment success rates (92.7–92.9%) (6,7), safety concerns have been raised, including one report of increased rates of significant pleural bleeding (16.1%) (7). At present, there is no robust evidence to support the use of once-daily IPFT, and no study has directly compared once-daily with twice-daily administration. In Singapore, separate real-world studies have reported on the use of IPFT in the management of pleural infections. Goh et al. evaluated concurrent versus sequential administration of IPFT across two institutions, within which 28 of 135 patients had received once-daily dosing (8), while Yong et al. reported outcomes from a cohort treated exclusively with a twice-daily regimen (9). By combining and re-analysing data from these two cohorts, the present study aimed to describe real-world treatment outcomes associated with once-daily and twice-daily IPFT regimens, and to compare their efficacy and safety. In addition, we examined outcomes among patients who received modified doses of alteplase compared with those treated with a standard, non-modified regimen. We present this article in accordance with the STROBE reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0680/rc). Methods This retrospective multicentre cohort study combines data from the studies by Goh et al. (8) and Yong et al. (9). As part of each of the respective studies, patients were identified from each hospital’s respective databases across various time points: Singapore General Hospital (SGH) between January 2017 and September 2022, Changi General Hospital (CGH) between January 2021 and June 2022, and Tan Tock Seng Hospital (TTSH) between July 2016 and November 2023. The extracted data were detailed in the respective studies (8,9). Across all cohorts, pleural infection was diagnosed using a consistent criterion, defined as a compatible clinical history together with one or more supportive pleural fluid findings: (I) macroscopic purulence; (II) detection of bacteria by Gram stain or culture; or (III) pleural fluid pH ≤7.20 and/or glucose ≤3.0 mmol/L. All patients were managed with tube thoracostomy and systemic antibiotics in accordance with international guidelines and local practice. The decisions to initiate IPFT, including the initial alteplase dose, dosing frequency (twice-daily vs. once-daily), and referral for surgical intervention were left to the discretion of the managing physician, thereby reflecting real-world practice. The dose of DNase was a standard 5 mg. The preparation and administration protocols for tPA and DNase have been detailed in the respective studies (8,9). The primary outcome was treatment success, defined as survival at 30 days without the need for surgical intervention or hospital readmission within the same period. This was analysed according to dosing frequency (twice-daily vs. once-daily) and alteplase dosing strategy [standard-dose (10 mg) vs. modified-dose (<10 mg)]. Secondary outcomes included changes in chest radiograph scores, hospital length of stay, 30-day mortality, readmission, requirement for surgery within 30 days, and treatment-related complications. Pleural bleeding was defined as the presence of haemorrhagic pleural fluid associated with an acute haemoglobin decrease requiring blood transfusion or surgical intervention. The derivation of chest radiograph scores has been described previously (1). In an additional exploratory analysis, patients were categorised into three clinically defined regimen groups: (A) guideline-based (alteplase 10 mg twice-daily for 6 doses); (B) standard-dose (alteplase 10 mg) twice-daily regimens not meeting guideline duration (<6 or >6 doses); and (C) modified regimens, defined by any deviation in alteplase dose (<10 mg), dosing frequency (once daily), or treatment duration. Statistical analysis Summary statistics, including mean, standard deviation (SD), median, interquartile range (IQR), minimum, and maximum values, were reported for continuous variables. Counts and percentages were reported for categorical variables. T-tests or Wilcoxon rank-sum tests were used to compare continuous variables between groups, and chi-square tests or Fisher’s exact tests were used to compare categorical variables. Missing data were omitted from analysis. Logistic regression analyses were performed to assess the impact of dosing frequency and dose modification on treatment outcomes. Inverse probability weighted (IPW) logistic regression was also applied to compare twice-daily and once-daily doses on the binary outcomes. Odds ratio (OR) and the corresponding 95% confidence intervals (CIs) were presented. All tests were two-sided with statistical significance defined as P<0.05. Statistical analysis was performed using R Studio (version 4.4.1). Results Overall patient and pleural fluid characteristics A total of 266 patients were included: 131 (49.3%) were from TTSH, 104 (39.1%) from SGH, and 31 (11.7%) from CGH. The mean age was 64 years; 206 patients (77.4%) were male, and the median Charlson Comorbidity Index (CCI) was 3. The median RAPID (renal, age, purulence, infection source, dietary factors) score was 3, with 130 patients (50.8%) classified as medium risk. Median antibiotic duration was 42 days (Table 1). Baseline patient characteristics were broadly similar across centres, with no significant differences in disease severity based on RAPID score (Table S1). Table 1Patient characteristics and treatment received: overall and stratified by dosing regimen (twice-daily vs. once-daily)VariableNOverallTwice-daily (N=238)Once-daily (N=28)P valueAge (years), mean (SD)26664 (14.2)64 (14.5)67 (10.1)0.26Gender, n (%)266 Male 206 (77.4)185 (77.7)21 (75.0)– Female60 (22.6)53 (22.3)7 (25.0)–CCI, median (range)2663 (0, 13)3 (0, 13)3 (1, 9)0.20RAPID score, median (range)256†3 (1, 6)3.57 (1, 5)3.5 (1, 6)0.47 Low risk (0–2), n (%)71 (27.8)63 (27.6)8 (28.6)– Medium risk (3–4), n (%)130 (50.8)119 (52.2)11 (39.3)– High risk (5–7), n (%)55 (21.4)46 (20.2)9 (32.1)–Antiplatelet use, n (%)26652 (19.5)49 (20.6)3 (10.7)0.21Anticoagulant use, n (%)2668 (3.0)8 (3.4)0 (0)0.99Time to 1st dose of IPFT (days)‡, median (range)263†4 (0, 67)4 (0, 67)2 (0, 29)0.004IPFT within 48 hours, n (%)263†102 (38.8)82 (34.9)20 (71.4)<0.001Number of doses, median (range)2665.5 (1, 13)6 (1, 13)3 (1, 3)<0.001Alteplase dose (mg), median (range)26310 (0.5, 10)5 (0.5, 10)10 (5, 10)<0.001Antibiotic duration (days), median (range)246†42 (7, 133)42 (7, 133)28 (14, 43)0.004P values were calculated using Wilcoxon rank-sum test, Fisher’s exact test, or Pearson’s Chi-squared test as appropriate. †, RAPID data were unavailable for 10 patients, IPFT timing data and median alteplase dose were unavailable for 3 patients, and antibiotics duration data were unavailable for 20 patients; ‡, measured from chest tube insertion to first dose of IPFT. CCI, Charlson Comorbidity Index; IPFT, intrapleural fibrinolytic therapy; RAPID, renal, age, purulence, infection source, dietary factors; SD, standard deviation. Patient characteristics and treatment received: overall and stratified by dosing regimen (twice-daily vs. once-daily) P values were calculated using Wilcoxon rank-sum test, Fisher’s exact test, or Pearson’s Chi-squared test as appropriate. †, RAPID data were unavailable for 10 patients, IPFT timing data and median alteplase dose were unavailable for 3 patients, and antibiotics duration data were unavailable for 20 patients; ‡, measured from chest tube insertion to first dose of IPFT. CCI, Charlson Comorbidity Index; IPFT, intrapleural fibrinolytic therapy; RAPID, renal, age, purulence, infection source, dietary factors; SD, standard deviation. Overall, 44 patients (16.7%) presented with purulent pleural fluid, and pleural fluid cultures were positive in 103 (38.7%). Hospital-acquired pleural infection accounted for 43 cases (16.2%). The median pleural fluid pH, lactate dehydrogenase (LDH), and glucose were 7.26, 1,737 IU/L, and 3.6 mmol/L, respectively. Patients from TTSH had a lower median pleural fluid pH and higher median LDH compared with those from SGH and CGH (Table S1). The median time from chest tube insertion to the first dose of IPFT was 4 days, and 102 patients (38.8%) received fibrinolytic therapy within 48 hours of chest tube insertion. Across centres, early IPFT administration (within 48 hours) was more frequent in SGH and CGH than in TTSH (64.5% and 57.8% vs. 17.7%, P<0.001), corresponding to a shorter median time to first IPFT dose (2 days and 2 days vs. 6.5 days, P<0.001) (Table S1). Twice-daily dosing versus once-daily dosing Twice-daily dosing was administered in 238 patients (89.5%), while 28 patients (10.5%) received once-daily dosing. The median number of IPFT doses administered was 6 (range: 1, 13) and 3 (range: 1, 3), and median alteplase doses were 5 mg (range: 0.5, 10) and 10 mg (range: 5, 10), respectively. There was no significant difference in patient characteristics or median RAPID scores between the 2 dosing regimens. Patients receiving once-daily dosing were initiated on IPFT earlier, with a median time from chest tube insertion to first dose of 2 days compared with 4 days in the twice-daily group (P=0.004). A greater proportion of once-daily patients received IPFT within 48 hours (71.4% vs. 34.9%, P<0.001) (Table 1). Dosing frequency and treatment outcomes The overall treatment success rate was 83.1%. By dosing regimen, treatment success was achieved in 195 patients (81.9%) who received twice-daily dosing and 26 patients (92.9%) who received once-daily dosing (P=0.19). Surgical intervention within 30 days was required in 6 patients (2.5%) in the twice-daily group and in none from the once-daily group (P>0.99). Readmissions occurred in 24 patients (10.1%) receiving twice-daily dosing, while no readmissions were reported in the once-daily group (P=0.09). Thirty-day mortality was comparable between groups, with 14 deaths (5.9%) in the twice-daily group and 2 deaths (7.1%) in the once-daily group (P=0.68). Median hospital length of stay was significantly shorter in the once-daily group compared with the twice-daily group [12.5 (range: 4, 90) versus 18.5 (range: 4, 438) days, P=0.02]. The median change in chest radiograph scores did not differ significantly between regimens [−15.1% (−58%, 0.5%) vs. −16.6% (−84.6%, 92.4%), P=0.91]. There were no episodes of pleural bleeding reported in the once-daily dosing group, while 17 patients (7.1%) in the twice-daily group experienced pleural bleeding (Table 2). Table 2Comparison of treatment outcomes between twice-daily and once-daily dosing regimensOutcomesNTwice-daily (N=238)Once-daily (N=28)P valueTreatment success, n (%)266195 (81.9)26 (92.9)0.19Surgery within 30 days, n (%)2666 (2.5)0 (0)>0.99Readmission, n (%)26624 (10.1)0 (0)0.0930-day mortality, n (%)26614 (5.9)2 (7.1)0.68Length of stay (days), median (range)26618.5 (4, 438)12.5 (4, 90)0.02Change in CXR score (%), median (range)236†−16.6 (−84.6, 92.4)−15.1 (−58, 0.5)0.91Bleeding, n (%)26617 (7.1)0 (0)0.23P values were calculated using Wilcoxon rank-sum test, Fisher’s exact test, or Pearson’s Chi-squared test as appropriate. †, data was not available for 30 patients. CXR, chest X-ray. Comparison of treatment outcomes between twice-daily and once-daily dosing regimens P values were calculated using Wilcoxon rank-sum test, Fisher’s exact test, or Pearson’s Chi-squared test as appropriate. †, data was not available for 30 patients. CXR, chest X-ray. Effect of dosing frequency on treatment outcomes Logistic regression analyses were performed to assess the impact of dosing frequency on treatment success and 30-day mortality. Models were not fitted for surgery within 30 days or readmission as none were reported in the once-daily group. In multivariable models, dosing frequency was included as a factor, adjusting for age, CCI, time from chest tube insertion to 1st dose, and initiation of IPFT within 48 hours (Table S2). These variables were selected a priori given their recognized relevance as risk factors associated with pleural infections. Inverse probability of treatment weighting (IPTW) based on propensity scores was used to adjust for baseline differences between treatment groups. Propensity scores were estimated using a logistic regression model for dosing and including age, CCI, time from chest tube insertion to first dose, and fibrinolytic administration within 48 hours. Stabilized weights were calculated using probability of treatment divided by the estimated propensity score for treated patients, and the probability of no treatment divided by one minus the propensity score for untreated patients. Weighted logistic regression was then used to estimate the association between 24-hour dosing and treatment success. All models yielded consistent estimates, and no statistically significant association was observed between dosing frequency and treatment success or 30-day mortality (Table 3). Similarly, in quasi-Poisson regression analyses evaluating hospital length of stay, dosing frequency was not significantly associated with duration of hospitalization (P=0.21). Table 3Effect of dosing regimen on treatment outcomes (once-daily vs. twice-daily dosing)OutcomesModelOdds ratio (95% CI)P valueTreatment successUnivariate logistic regression2.87 (0.81, 18.21)0.16Multiple logistic regression2.34 (0.62, 15.33)0.27IPW-weighted logistic regression1.55 (0.54, 6.03)0.4630-day mortalityUnivariate logistic regression1.23 (0.19, 4.74)0.79Multiple logistic regression1.35 (0.19, 6.02)0.72IPW-weighted logistic regression2.21 (0.54, 7.02)0.21The multivariable logistic regression model included once-daily dosing as a factor, adjusting for age, CCI, time from chest tube insertion to 1st dose, and fibrinolytics within 48 hours. CCI, Charlson Comorbidity Index; CI, confidence interval; IPW, inverse probability weighted. Effect of dosing regimen on treatment outcomes (once-daily vs. twice-daily dosing) The multivariable logistic regression model included once-daily dosing as a factor, adjusting for age, CCI, time from chest tube insertion to 1st dose, and fibrinolytics within 48 hours. CCI, Charlson Comorbidity Index; CI, confidence interval; IPW, inverse probability weighted. In addition, alteplase dose modification was included in the multivariable logistic regression models. The interaction between dosing frequency and dose modification was not statistically significant, and neither variable demonstrated a significant association with treatment success (Table S3). Dose modification and treatment outcomes A total of 132 patients received 10 mg of alteplase as part of their IPFT regimen, while 131 patients received a modified dose of alteplase (<10 mg). The median modified alteplase dose was 5 mg. Data on alteplase dosing was not available for 3 patients. Between these groups (no dose modification vs. modified dose), the mean age and median CCI were comparable. Although the mean RAPID score differed statistically between the two groups (3.31 vs. 3.45; P<0.001), the absolute difference was small, and the median values were identical at 3 (range: 1, 6). Patients who received a modified dose of alteplase had a longer interval to first dose of IPFT (median 6 vs. 2 days, P<0.001), lower proportion who had received IPFT within 48 hours (20.2% vs. 57.2%, P<0.001), and longer median hospital length of stay (24 vs. 14 days, P<0.001). The improvement in median chest X-ray (CXR) score was also lower in the modified dose group (−12.8% vs. −20.1%, P=0.02). Readmission rates were higher (14.5% vs. 3.8%, P=0.003), but 30-day mortality rates were lower (3.1% vs. 9.1%, P=0.04). There was no significant difference in treatment success or bleeding rates between the 2 groups (Table 4). Table 4Comparison of patient characteristics and treatment outcomes between non-modified dose and modified dose groupsVariableNNon-modified dose (alteplase 10 mg) (N=132)Modified dose (alteplase <10 mg) (N=131)P valueAge (years), mean (SD)263†63.2 (13.3)65.1 (15.0)0.30CCI, median (range)263†3 (0, 10)3 (0, 13)0.49RAPID score254‡<0.001 Mean (SD)3.31 (1.39)3.45 (1.18) Median (range)3 (1, 6)3 (1, 6)Time to 1st dose of IPFT (days)§, median (range)260‡2 (0, 36)6 (0, 67)<0.001IPFT within 48 hours, n (%)260‡75 (57.2)26 (20.2)<0.001Length of stay (days), median (range)26314 (4, 92)24 (5, 438)<0.001Readmission, n (%)2635 (3.8)19 (14.5)0.00330-day mortality, n (%)26312 (9.1)4 (3.1)0.04Surgery within 30 days, n (%)2633 (2.3)3 (2.3)>0.99Change in CXR score (%), median (range)234−20.1 (−73, 65)−12.8 (−84.6, 92.4)0.02Treatment success, n (%)263113 (85.6)105 (80.2)0.24Bleeding, n (%)26310 (7.6)7 (5.3)0.46P values were calculated using Wilcoxon rank-sum test; Pearson’s Chi-squared test; Fisher’s exact test. †, data were unavailable for 3 patients; ‡, RAPID score data were unavailable for 12 patients, IPFT timing data were unavailable for 6 patients; §, measured from chest tube insertion to first dose of IPFT. CCI, Charlson Comorbidity Index; CXR, chest X-ray; IPFT, intrapleural fibrinolytic therapy; RAPID, renal, age, purulence, infection source, dietary factors; SD, standard deviation. Comparison of patient characteristics and treatment outcomes between non-modified dose and modified dose groups P values were calculated using Wilcoxon rank-sum test; Pearson’s Chi-squared test; Fisher’s exact test. †, data were unavailable for 3 patients; ‡, RAPID score data were unavailable for 12 patients, IPFT timing data were unavailable for 6 patients; §, measured from chest tube insertion to first dose of IPFT. CCI, Charlson Comorbidity Index; CXR, chest X-ray; IPFT, intrapleural fibrinolytic therapy; RAPID, renal, age, purulence, infection source, dietary factors; SD, standard deviation. Effect of Alteplase dose modification on treatment outcomes In univariate analysis, dose modification was associated with a significantly lower 30-day mortality (OR 0.31, 95% CI: 0.08–0.93; P=0.05) and higher odds of readmission (OR 4.31, 95% CI: 1.67–13.33; P=0.004). No significant associations were observed with treatment success, bleeding, or surgery within 30 days. After adjustment for age, CCI, time from chest tube insertion to first dose, and use of fibrinolytics within 48 hours, dose modification continued to remain associated with lower 30-day mortality (adjusted OR 0.19, 95% CI: 0.04–0.64; P=0.01), while the association with readmission was no longer statistically significant (adjusted OR 2.78, 95% CI: 0.97–9.28; P=0.07). There were no significant differences in treatment success, bleeding complications, or need for surgery within 30 days after adjustment (Table 5). Table 5Logistic regression models to investigate the effect of dose modification on the outcomes (modified vs. non-modified dose)OutcomesModelOdds ratio (95% CI)P valueTreatment successUnivariate logistic regression0.68 (0.35, 1.29)0.24Multiple logistic regression1.07 (0.51, 2.25)0.8530-day mortalityUnivariate logistic regression0.31 (0.08, 0.93)0.05Multiple logistic regression0.19 (0.04, 0.64)0.01ReadmissionUnivariate logistic regression4.31 (1.67, 13.33)0.004Multiple logistic regression2.78 (0.97, 9.28)0.07Surgery within 30 daysUnivariate logistic regression1.01 (0.18, 5.53)0.99Multiple logistic regression0.93 (0.15, 5.68)0.93BleedingUnivariate logistic regression0.69 (0.24, 1.85)0.46Multiple logistic regression0.55 (0.17, 1.66)0.29The multivariable logistic regression model included dose modification as a factor, adjusting for age, CCI, time from chest tube insertion to 1st dose, and fibrinolytics within 48 hours. CCI, Charlson Comorbidity Index; CI, confidence interval. Logistic regression models to investigate the effect of dose modification on the outcomes (modified vs. non-modified dose) The multivariable logistic regression model included dose modification as a factor, adjusting for age, CCI, time from chest tube insertion to 1st dose, and fibrinolytics within 48 hours. CCI, Charlson Comorbidity Index; CI, confidence interval. Comparison by clinically defined regimen groups Patients were further categorised into three clinically defined regimen groups: guideline-based (Group A), standard-dose twice-daily regimens not meeting guideline duration (Group B), and modified regimens incorporating deviations in dose, frequency, or duration (Group C). Baseline characteristics were broadly similar across groups with respect to age, sex distribution, and comorbidity burden, with comparable median RAPID score. However, the treatment received differed between groups: patients in Group C had a longer median time to initiation of IPFT (P<0.001), whereas early administration within 48 hours was more frequent in Group B (P<0.001) (Table 6). Table 6Comparison by clinically-defined regimen groupsVariableNGroup A (N=42)Group B (N=69)Group C (N=155)P valueAge (years), mean (SD)26661 (15.2)63 (12.7)65.7 (14.4)0.13Gender2660.32 Male, n (%)36 (85.71)54 (78.26)116 (74.84)– Female, n (%)6 (14.29)15 (21.74)39 (25.16)–CCI, median (range)2662 (0, 10)3 (0, 9)3 (0, 13)0.33RAPID score, median (range)256†3 (1, 6)3 (1, 6)3 (1, 6)0.03Time to 1st dose of IPFT (days)‡, median (range)263†3 (0, 21)2 (0, 36)5 (0, 67)<0.001IPFT within 48 hours, n (%)263†18 (42.86)42 (61.76)42 (27.45)<0.001Antibiotic duration (days), median (range)246†42 (14, 104)28 (7, 90)42 (13, 133)<0.001Treatment success, n (%)26635 (83.3)59 (85.5)127 (81.9)0.80Surgery within 30 days, n (%)2662 (4.8)1 (1.5)3 (1.9)0.51Readmission, n (%) 2664.0 (9.5)1.0 (1.5)19.0 (12.3)0.0230-day mortality, n (%)2662.00 (4.76)8.00 (11.59)6.00 (3.87)0.08Length of stay (days), median (range)26614.5 (7, 88)13 (4, 92)23 (4, 438)<0.001Change in CXR score (%), median (range)236†−15.2 (−68.0, 12.3)−25.0 (−73.0, 65.0)−13.3 (−84.6, 92.4)0.02Bleeding, n (%)2661 (2.4)9 (13.0)7 (4.5)0.042Group A: alteplase 10 mg BD × 6 doses; Group B: alteplase 10 mg BD with a dose count other than 6 doses; Group C: other modified regimens. P values were calculated using Kruskal-Wallis rank-sum test, Pearson’s Chi-squared test, or Fisher’s exact test as appropriate. †, RAPID data were unavailable for 10 patients, IPFT timing data were unavailable for 3 patients, antibiotics duration data were unavailable for 20 patients, and CXR data were unavailable for 30 patients; ‡, measured from chest tube insertion to first dose of IPFT. BD, twice daily; CCI, Charlson Comorbidity Index; CXR, chest X-ray; IPFT, intrapleural fibrinolytic therapy; RAPID, renal, age, purulence, infection source, dietary factors; SD, standard deviation. Comparison by clinically-defined regimen groups Group A: alteplase 10 mg BD × 6 doses; Group B: alteplase 10 mg BD with a dose count other than 6 doses; Group C: other modified regimens. P values were calculated using Kruskal-Wallis rank-sum test, Pearson’s Chi-squared test, or Fisher’s exact test as appropriate. †, RAPID data were unavailable for 10 patients, IPFT timing data were unavailable for 3 patients, antibiotics duration data were unavailable for 20 patients, and CXR data were unavailable for 30 patients; ‡, measured from chest tube insertion to first dose of IPFT. BD, twice daily; CCI, Charlson Comorbidity Index; CXR, chest X-ray; IPFT, intrapleural fibrinolytic therapy; RAPID, renal, age, purulence, infection source, dietary factors; SD, standard deviation. Treatment success rates were similar across groups (83.3% in Group A, 85.5% in Group B, and 81.9% in Group C; P=0.80), with no statistically significant differences in 30-day mortality or requirement for surgery. Pairwise comparisons between groups were performed with Holm-Bonferroni adjustment to control the family-wise error rate. No statistically significant differences were observed following adjustment: Group B demonstrated higher observed odds of pleural bleeding (OR 3.17, 95% CI: 0.90–11.25; adjusted P=0.06) and 30-day mortality (OR 3.26, 95% CI: 0.85–12.43; adjusted P=0.07) compared with Group C. Conversely, lower observed odds of readmission were noted in Group B (OR 0.11, 95% CI: 0.01–1.26; adjusted P=0.06), but this did not meet statistical significance either (Table 7). Table 7Pairwise comparisons between groupsOutcomesOdds ratio (95% CI)P valueTreatment success Group A vs. C1.10 (0.36, 3.35)>0.99 Group B vs. C1.30 (0.50, 3.39)>0.99Bleeding Group A vs. C0.51 (0.04, 6.89)0.54 Group B vs. C3.17 (0.9, 11.25)0.06Readmission Group A vs. C0.75 (0.19, 3.02)0.62 Group B vs. C0.11 (0.01, 1.26)0.0630-day mortality Group A vs. C1.24 (0.17, 9.21)0.79 Group B vs. C3.26 (0.85, 12.43)0.07Group A: alteplase 10 mg BD × 6 doses; Group B: alteplase 10 mg BD with a dose count other than 6 doses; Group C: other modified regimens. Group C was used as the reference group. P values were adjusted using the Holm-Bonferroni method. BD, twice daily; CI, confidence interval. Pairwise comparisons between groups Group A: alteplase 10 mg BD × 6 doses; Group B: alteplase 10 mg BD with a dose count other than 6 doses; Group C: other modified regimens. Group C was used as the reference group. P values were adjusted using the Holm-Bonferroni method. BD, twice daily; CI, confidence interval. Discussion The latest BTS guidelines and European Respiratory Society/European Society of Thoracic Surgeons (ERS/ESTS) consensus statements acknowledge real-world variations in the IPFT regimen; however, both continue to recommend a twice-daily regimen, citing a lack of comparative studies for once-daily regimens (10). To our knowledge, there is limited data evaluating outcomes associated with once-daily versus twice-daily IPFT in routine clinical practice. In clinical practice, IPFT is prescribed as a composite regimen incorporating dose, frequency and duration, with these factors often determined concurrently, posing challenges for comparative studies. We therefore sought to provide comparative real-world data on these dosing strategies within a multicentre retrospective cohort. In this study, neither dosing frequency nor dose modification was significantly associated with treatment success, surgical intervention within 30 days, readmission, or hospital length of stay after adjustment for key covariates and propensity weighting. Similarly, exploratory analyses comparing guideline-based treatment regimens to modified regimens demonstrated no statistically significant differences in treatment outcomes across groups. The overall treatment success rate in our cohort was 83.1%, with no significant difference between dosing regimens. This was slightly lower than the 84–93% success rates reported in previous studies evaluating various alteplase dosing strategies (2-4). The discrepancy may reflect differences in patient characteristics, as our cohort was older (mean age 64 vs. 55–61 years reported in prior studies) (1-4,6). Advancing age has been associated with poorer survival in pleural infection (9), and prognostic tools such as the RAPID score (11) similarly identify age as an important determinant of outcome. The timing of IPFT initiation may play an important role in determining treatment success. In our cohort, the median time to IPFT initiation was longer than that reported in prior studies (median 1–2 days), which reported higher treatment success rates (4,6,7). Delayed initiation may reflect more advanced disease chronicity or pleural organisation at the time of treatment, potentially reducing responsiveness to fibrinolysis. Patients in our cohort who received once-daily IPFT demonstrated a higher treatment success rate (92%); however, these patients were also more likely to have received therapy within 48 hours of chest tube insertion. This raises the possibility that earlier initiation, rather than dosing frequency per se, may have exerted a greater influence on treatment outcomes. Consistent with this interpretation, the median time to first IPFT dose in this group (2 days) was similar to that reported in other once-daily IPFT studies, which also demonstrated comparable success rates. Mehta et al. reported a protocolised initiation within 24 hours and a treatment success rate of 92.7% (6), while Jiang et al. reported a median time of 1 day with a treatment success rate of 92.9% (7). Although unadjusted analyses suggested a significantly shorter hospital stay among patients receiving once-daily IPFT, this association was not sustained after multivariable regression. As logistic regression analysis adjusted for covariates including age, CCI (which were otherwise similar between the groups), and time to first dose of IPFT, the univariate finding likely reflects a more aggressive and timely treatment approach in the once-daily group rather than a causal effect of dosing frequency itself. Nevertheless, this contrasts with findings from a previous study, which reported a longer chest tube duration and length of hospital stay in the once-daily group (7). Overall, this probably reflects differences in clinical practice rather than differences in dosing frequency, and further studies to evaluate this may be useful. No pleural bleeding events were observed among patients receiving once-daily IPFT in this study. While the number of patients in this group was small, the previously reported 16.1% incidence of bleeding was likewise derived from a limited cohort of 56 patients (7), wherein some patients were on antiplatelet/anticoagulants during IPFT. Variations in peri-procedural antiplatelet and anticoagulant management may partly account for these differences, as only one patient in our once-daily group was on antiplatelet therapy and none were anticoagulated. Adherence to contemporary recommendations regarding the temporary cessation of anticoagulants that have since been published may further reduce the risk of pleural bleeding (12). A lack of association between alteplase dose and treatment success remains a consistent finding across the literature. Interestingly, in this study, dose modification was independently associated with a lower 30-day mortality. However, it is possible that clinicians may have selectively modified doses in patients who were clinically less unstable, had less loculated effusions, or were perceived to have higher bleeding risks, thereby reflecting a form of implicit clinical triage rather than a direct protective effect of dose adjustment itself. A once-daily IPFT regimen offers several potential advantages. Each administration requires careful drug reconstitution, intrapleural delivery, and manipulation of the drainage system—procedures that demand familiarity and technical proficiency. Reducing the frequency of dosing may lower the cumulative risk of iatrogenic complications, including medication errors, infection, chest tube dislodgement, and drug-related adverse events. In our local practice, IPFT is predominantly administered by physicians; thus, after-hours dosing performed by on-call junior staff may further increase procedural risk. A once-daily regimen may mitigate these concerns while maintaining therapeutic efficacy. There are limitations to this study. Firstly, its retrospective nature precludes any conclusions on causation between dose frequency or modification and outcomes. Heterogeneity in the management of pleural infections introduces multiple confounders, including decisions on the frequency, selection, institutional practices or timing of doses, and availability of surgical expertise, which itself is the subject of several ongoing studies (13,14). Nonetheless, these findings reflect the real-world application of IPFT, and further randomised controlled trials to compare dosing frequencies are needed. Secondly, significantly fewer patients received once daily IPFT as compared to twice daily. Although multivariable adjustment and inverse probability-weighted analyses were applied to minimise confounding and improve covariate balance, limited sample size in the once-daily group may have reduced statistical power to detect modest but clinically relevant differences between regimens. In addition, zero-event outcomes, including surgery and readmission in the once-daily group, precluded model fitting for these endpoints. This also limited the ability to perform robust comparative analyses within the clinically defined modified regimen subgroup when comparing against guideline-recommended regimens. Lastly, the majority of once daily IPFT administration occurred in a single centre, where treatment success may be influenced by clinician behaviour and established protocols for IPFT. This may result in selection bias and limit the external validity of our findings. Consequently, estimates of effect for once-daily dosing should be interpreted with caution, and confirmation in larger, prospectively designed cohorts is warranted. Conclusions In conclusion, once-daily IPFT was associated with clinical outcomes comparable to a twice-daily regimen in this retrospective cohort, providing real-world data to inform ongoing discussions regarding optimal dosing strategies in pleural infection. Lower doses of alteplase were also associated with similar treatment success, consistent with prior studies. Earlier initiation of therapy appeared to be associated with more favourable outcomes, suggesting that treatment timing may be an important determinant of response. Prospective studies are needed to more definitively compare dosing strategies, particularly in Asian populations where data remain limited. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0680/rc Funding: None. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0680/coif). The authors have no conflicts of interest to declare. References Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0680/prf Supplementary Materials The article’s supplementary files as